The need for registry‐based studies in diabetes and stroke: A unique opportunity to understand whether diabetic treatments improve post‐stroke outcome

Darsalia, Vladimer; Vercalsteren, Ellen; Karampatsi, Dimitra; Romanitan, Mihaela Oana; Mazya, Michael V.; Nyström, Thomas; Patrone, Cesare

doi:10.1111/dom.15577

Diabetes Obesity Metabolism

2024

DOI: 10.1111/dom.15577

|View full text |Cite

The need for registry‐based studies in diabetes and stroke: A unique opportunity to understand whether diabetic treatments improve post‐stroke outcome

Vladimer Darsalia,

Ellen Vercalsteren,

Dimitra Karampatsi

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Comparing clinical outcomes in patients with type 2 diabetes mellitus after ischaemic stroke: Sodium–glucose cotransporter 2 inhibitors users versus non‐users. A propensity score matching National Cohort Study

Chen,

Lee,

Chan

et al. 2024

Diabetes Obesity Metabolism

View full text Add to dashboard Cite

AimThis nationwide cohort study evaluated the impact of sodium–glucose co‐transporter‐2 inhibitors (SGLT2i) on patients with type 2 diabetes mellitus (T2DM) after ischaemic stroke (IS), aiming to compare clinical outcomes between SGLT2i‐treated patients and those not receiving SGLT2i.Materials and MethodsUtilizing Taiwan's National Health Insurance Research Database, we identified 707 patients with T2DM treated with SGLT2i and 27 514 patients not treated with SGLT2i after an IS, respectively, from 1 May 2016 to 31 December 2019. Propensity score matching was applied to balance baseline characteristics. The follow‐up period extended from the index date (3 months after the index acute IS) until the independent occurrence of the study outcomes, 6 months after discontinuation of the index drug, or the end of the study period (31 December 2020), whichever came first.ResultsAfter propensity score matching, compared with the non‐SGLT2i group (n = 2813), the SGLT2i group (n = 707) exhibited significantly lower recurrent IS rates (3.605% per year vs. 5.897% per year; hazard ratio: 0.55; 95% confidence interval: 0.34–0.88; p = 0.0131) and a significant reduction in all‐cause mortality (5.396% per year vs. 7.489% per year; hazard ratio: 0.58; 95% confidence interval: 0.39–0.85; p = 0.0058). No significant differences were observed in the rates of acute myocardial infarction, cardiovascular death, heart failure hospitalization, or lower limb amputation.ConclusionsOur findings indicate significantly lower risks of recurrent IS and all‐cause mortality among patients with T2DM receiving SGLT2i treatment. Further studies are required to validate these results and investigate the underlying mechanisms behind the observed effects.

show abstract

Comparing clinical outcomes in patients with type 2 diabetes mellitus after ischaemic stroke: Sodium–glucose cotransporter 2 inhibitors users versus non‐users. A propensity score matching National Cohort Study

Chen,

Lee,

Chan

et al. 2024

Diabetes Obesity Metabolism

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

The need for registry‐based studies in diabetes and stroke: A unique opportunity to understand whether diabetic treatments improve post‐stroke outcome

Cited by 1 publication

References 25 publications

Comparing clinical outcomes in patients with type 2 diabetes mellitus after ischaemic stroke: Sodium–glucose cotransporter 2 inhibitors users versus non‐users. A propensity score matching National Cohort Study

Comparing clinical outcomes in patients with type 2 diabetes mellitus after ischaemic stroke: Sodium–glucose cotransporter 2 inhibitors users versus non‐users. A propensity score matching National Cohort Study

Contact Info

Product

Resources

About